News

Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference

AUSTIN, Texas, May 16, 2017 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the UBS 2017 Global Healthcare Conference in New York on Tuesday, May 23 at 1:00 p.m. ET.

2017-06-27T11:56:11+00:00